Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L6
- Development stage
- Preclinical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
L6 is a code name used to refer to d-Histidine when it functions as a ligand in novel technetium(I) radiopharmaceutical complexes, such as [99mTc]-TcL6. These complexes are being investigated as tumor-seeking agents for cancer imaging, designed to exploit metabolic alterations in cancer cells. The d-Histidine ligand (L6) plays a role in the binding and accumulation properties of these targeted radiotracers. It is important to note that "L6" is a highly non-specific term and is used in various other contexts in scientific literature, including referring to cell lines, dietary components, anatomical structures, bacterial lineages, and chemical compounds.
- Other names
- d-Histidine ligand
Beyond the preview
Go deeper on L6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L6.